NOT YET RECRUITING
NCT07924722
Local Iloprost Therapy to Promote Bone Healing in High Risk Fractures
What is this study about? When a bone breaks, it usually heals within a few months. In some people, however, the bone does not heal properly (a "non-union"), which can mean ongoing pain, more surgery, and a longer time off work.
This study tests whether a single, local treatment with a medicine called iloprost, given right at the fracture site, can help bones heal better in people who are more likely to have healing problems.
Who can take part? Patients who need surgery to fix a broken bone and who are at higher risk of poor healing. A blood test before surgery measures a certain type of immune cell (CD8+ TEMRA cells). A high level (38% or more) indicates a higher risk. About 533 people will be tested to find 60 participants.
What happens during the study:
Surgery: Everyone receives the standard operation to fix the bone. During surgery, a thin, soft tube (catheter) is placed near the fracture, similar to those routinely used to deliver pain medication to wounds.
Groups: Participants are assigned by chance (like a coin toss) to one of two equal groups:
Group 1: iloprost through the tube for 24 hours Group 2: a harmless salt-water solution (placebo) for 24 hours Timing: In both groups, salt water runs for the first 24 hours after surgery. The next 24 hours bring either iloprost or placebo. Treatment lasts 48 hours in total.
Blinding: Participants, doctors, nurses, and the people who assess the results do not know who receives which treatment. Only the pharmacy staff who prepare the infusions know, and they are not involved in patient care. This keeps the results fair and unbiased.
What happens afterwards?
Participants are followed for about one year (52 weeks), with clinic visits at weeks 6, 18, and 36 and a phone call at week 52.
How will we know if it worked? The main question is whether the bone has healed by week 18, as seen on a CT scan. The study also looks at bone healing at week 36, pain, physical function, quality of life, return to work, and changes in immune cells and blood markers, which help explain how the treatment works.
How is safety monitored? All side effects are recorded and compared between the two groups to see how safe and well tolerated the treatment is.
Why does this matter? Currently, there are few ways to prevent healing problems before they occur. If the treatment works, it could help patients heal faster and avoid further operations. This is an early-stage (phase II) study at a single center. It can show whether the treatment is promising, but it cannot yet prove that it should become standard care.
Gender: All
Ages: 18 Years - 80 Years
Nonunion Bone Fracture
Fractures Ununited
Fractures